Cambrex Corporation (NYSE:CBM) CEO Steven M. Klosk sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the completion of the sale, the chief executive officer now owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cambrex Corporation (NYSE:CBM) opened at 56.00 on Friday. Cambrex Corporation has a 52 week low of $38.30 and a 52 week high of $62.95. The firm has a market capitalization of $1.83 billion, a P/E ratio of 20.40 and a beta of 2.28. The firm has a 50-day moving average of $52.67 and a 200 day moving average of $55.32.

Cambrex Corporation (NYSE:CBM) last posted its earnings results on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.76. The firm had revenue of $134.55 million for the quarter, compared to the consensus estimate of $136.82 million. Cambrex Corporation had a net margin of 17.70% and a return on equity of 24.25%. The company’s revenue was up 13.4% on a year-over-year basis. During the same period last year, the firm posted $0.68 EPS. On average, equities research analysts expect that Cambrex Corporation will post $3.08 EPS for the current fiscal year.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/cambrex-corporation-cbm-ceo-sells-219840-00-in-stock/1612111.html.

Several equities research analysts have weighed in on the stock. BidaskClub downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. ValuEngine upgraded shares of Cambrex Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded shares of Cambrex Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $65.67.

Several hedge funds and other institutional investors have recently bought and sold shares of CBM. Creative Planning grew its position in shares of Cambrex Corporation by 162.6% in the 2nd quarter. Creative Planning now owns 1,765 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 1,093 shares during the last quarter. Nisa Investment Advisors LLC grew its position in shares of Cambrex Corporation by 9.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,760 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 150 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Cambrex Corporation in the 1st quarter valued at $109,000. YorkBridge Wealth Partners LLC grew its position in shares of Cambrex Corporation by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 97 shares during the last quarter. Finally, Ameritas Investment Partners Inc. purchased a new position in shares of Cambrex Corporation in the 1st quarter valued at $151,000. 98.28% of the stock is currently owned by hedge funds and other institutional investors.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Insider Buying and Selling by Quarter for Cambrex Corporation (NYSE:CBM)

Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.